{"id":395491,"date":"2021-12-23T00:00:00","date_gmt":"2021-12-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0009-2021-biopharma-cell-therapies-in-oncology-clinical-pipeline-analysis-development-trends-g7-and-china-2021\/"},"modified":"2026-03-31T10:41:34","modified_gmt":"2026-03-31T10:41:34","slug":"sptoon0009-2021-biopharma-cell-therapies-in-oncology-clinical-pipeline-analysis-development-trends-g7-and-china-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoon0009-2021-biopharma-cell-therapies-in-oncology-clinical-pipeline-analysis-development-trends-g7-and-china-2021\/","title":{"rendered":"Cell Therapies in Oncology: Clinical Pipeline Analysis &#038; Development Trends | G7 and China | 2021"},"content":{"rendered":"<p>Cell therapy uses viable healthy cells to replace, expand, and\/or enhance a population of cells in order to achieve a therapeutic effect against a disease. The cell therapy field is rapidly expanding and claims the largest number of immuno-oncology therapies in clinical development. Chimeric antigen receptor (CAR) T-cell therapies lead the way; six treatments are already approved for hematological malignancies. Although CAR T cells dominate the pipeline, other cell therapies are beginning to gain traction, including tumor-infiltrating lymphocyte (TIL) therapies, T-cell receptor (TCR) therapies, and natural killer (NK) cell therapies. This Special Topics report provides a comprehensive view of the current cell therapy landscape and pipeline, with coverage of therapies in early-phase through late-phase development in a range of oncology indications.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What is the current landscape for approved CAR T-cell therapies? What are the key trends? What impact will these treatments have on their respective oncology indications?<\/li>\n<li>What does the cell therapy pipeline look like by phase of development? What are the key classes of therapies? Who are the key developers? In which geographies is development focused?<\/li>\n<li>What are the key trends in the development of cell therapies? In which oncology indications are cell therapies being investigated? What are the key targets in solid and hematological tumors?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan, and China.<\/p>\n<p>Primary and secondary market research: In-depth interviews with six key opinion leaders (hematologist-oncologists and medical-oncologists); analysis of industry and company reports; peer-reviewed journals; pipeline databases; industry \/ scientific conferences; news; media<\/p>\n<p>Therapies covered:<\/p>\n<ul>\n<li>Current therapies: CAR T-cell therapies (e.g., Yescarta, Kymriah, Tecartus, Breyanzi, Abecma, Carteyva) and dendritic-cell therapies (e.g., Provenge)<\/li>\n<li>Emerging therapies: Therapies in Phase III development, including CAR T-cell therapies, TIL therapies, TCR therapies, NK-cell therapies; coverage of select early-phase cell therapies<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Clarivate\u2019s <em>Special Topics<\/em> reports assess key trends in dynamic disease areas. This report offers a comprehensive pipeline analysis of the cell therapy landscape in relevant oncology indications.<\/p>\n","protected":false},"template":"","class_list":["post-395491","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-oncology","biopharma-geography-china","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395491\/revisions"}],"predecessor-version":[{"id":576317,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395491\/revisions\/576317"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=395491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}